选择性PARP-1抑制剂的研究进展

Advances in Selective PARP-1 Inhibitors

目前,已上市或处于临床阶段的PARP-1抑制剂普遍缺乏选择性,在抑制PARP-1同时也抑制PARP-2,从而带来较为严重的副作用。因此,选择性PARP-1抑制剂具有很大的开发前景。本文对选择性PARP-1抑制剂的研发现状作一介绍。

Currently, PARP-1 inhibitors launched or clinical suffer from the lack of selectivity. They may cause serious side effects due to the inhibition of PARP-2. Therefore, development of selective PARP-1 inhibitors is in urgent need. This paper briefly reviews the progress on the development of selective PARP-1 inhibitors.